Piramal Pharma Limited (NSE: PPLPHARMA)
226.31
+6.72 (3.06%)
Sep 6, 2024, 3:30 PM IST
Piramal Pharma Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | - | 3,568 | 1,956 | 2,281 | 3,847 |
Short-Term Investments | - | - | 1 | 7.1 | 31.2 |
Trading Asset Securities | - | 1,447 | 4,271 | 504 | - |
Cash & Short-Term Investments | 5,015 | 5,015 | 6,228 | 2,792 | 3,878 |
Cash Growth | -19.47% | -19.47% | 123.06% | -28.00% | - |
Accounts Receivable | - | 21,348 | 18,144 | 18,086 | 16,081 |
Other Receivables | - | 158.9 | 35.6 | 141.9 | 447 |
Receivables | - | 21,507 | 18,179 | 18,228 | 16,528 |
Inventory | - | 21,759 | 16,814 | 13,888 | 12,320 |
Prepaid Expenses | - | 640.2 | 765.7 | 695.5 | 626.6 |
Restricted Cash | - | 1,112 | 1,021 | 913.5 | 122.3 |
Other Current Assets | - | 4,612 | 5,347 | 4,155 | 3,012 |
Total Current Assets | - | 54,645 | 48,355 | 40,672 | 36,487 |
Property, Plant & Equipment | - | 48,160 | 44,415 | 37,157 | 31,663 |
Long-Term Investments | - | 2,403 | 2,119 | 2,168 | 1,227 |
Goodwill | - | 11,226 | 11,075 | 10,305 | 8,565 |
Other Intangible Assets | - | 31,672 | 33,382 | 33,053 | 27,094 |
Long-Term Accounts Receivable | - | - | 18.6 | 750.6 | 581.8 |
Long-Term Deferred Tax Assets | - | 3,865 | 3,493 | 2,973 | 2,441 |
Other Long-Term Assets | - | 1,149 | 2,369 | 892 | 939.7 |
Total Assets | - | 153,118 | 145,226 | 127,970 | 108,998 |
Accounts Payable | - | 15,384 | 11,927 | 10,264 | 9,179 |
Accrued Expenses | - | 2,448 | 2,642 | 2,141 | 1,943 |
Short-Term Debt | - | 11,714 | 13,023 | 6,588 | 3,605 |
Current Portion of Long-Term Debt | - | 9,037 | 8,189 | 7,424 | 2,105 |
Current Portion of Leases | - | 333.1 | 303.9 | 184.4 | 214.9 |
Current Income Taxes Payable | - | 403 | 35.4 | 716.6 | 394.2 |
Current Unearned Revenue | - | 2,003 | 859 | 452.7 | 770.3 |
Other Current Liabilities | - | 2,371 | 1,451 | 2,564 | 6,691 |
Total Current Liabilities | - | 43,693 | 38,431 | 30,333 | 24,903 |
Long-Term Debt | - | 24,838 | 33,835 | 26,221 | 23,392 |
Long-Term Leases | - | 1,180 | 1,019 | 862 | 934.1 |
Long-Term Unearned Revenue | - | 368.7 | 335.6 | 460.3 | 1,427 |
Long-Term Deferred Tax Liabilities | - | 2,292 | 2,193 | 1,920 | 2,225 |
Other Long-Term Liabilities | - | 1,311 | 1,471 | 1,082 | 0.8 |
Total Liabilities | - | 74,004 | 77,491 | 61,004 | 52,948 |
Common Stock | - | 13,230 | 11,933 | 11,859 | 9,946 |
Additional Paid-In Capital | - | 47,250 | 38,187 | 37,252 | 32,495 |
Retained Earnings | - | 9,707 | 9,564 | 11,589 | 8,326 |
Comprensive Income & Other | - | 8,928 | 8,050 | 6,267 | 5,284 |
Shareholders' Equity | 79,114 | 79,114 | 67,735 | 66,966 | 56,050 |
Total Liabilities & Equity | - | 153,118 | 145,226 | 127,970 | 108,998 |
Total Debt | 47,102 | 47,102 | 56,371 | 41,279 | 30,251 |
Net Cash (Debt) | -42,087 | -42,087 | -50,143 | -38,487 | -26,373 |
Net Cash Per Share | -32.13 | -32.79 | -42.13 | -32.65 | -42.02 |
Filing Date Shares Outstanding | 1,323 | 1,323 | 1,193 | 1,186 | 994.6 |
Total Common Shares Outstanding | 1,323 | 1,323 | 1,193 | 1,186 | 994.6 |
Working Capital | - | 10,952 | 9,924 | 10,339 | 11,584 |
Book Value Per Share | 59.80 | 59.80 | 56.76 | 56.47 | 56.35 |
Tangible Book Value | 36,216 | 36,216 | 23,278 | 23,608 | 20,391 |
Tangible Book Value Per Share | 27.38 | 27.38 | 19.51 | 19.91 | 20.50 |
Land | - | 1,729 | 1,339 | 1,300 | 1,284 |
Buildings | - | 18,949 | 15,260 | 11,996 | 10,208 |
Machinery | - | 41,626 | 36,473 | 30,662 | 26,853 |
Construction In Progress | - | 5,657 | 8,529 | 6,732 | 3,995 |
Source: S&P Capital IQ. Standard template. Financial Sources.